1 Min Read
March 27 (Reuters) - Cellectar Biosciences Inc:
* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.